SeqOne Genomics is a technology company.
SeqOne Genomics has raised $26.0M across 2 funding rounds.
SeqOne Genomics has raised $26.0M in total across 2 funding rounds.
SeqOne Genomics has raised $26.0M in total across 2 funding rounds.
SeqOne Genomics's investors include Dispersion Capital, Elaia Partners, Khosla Ventures, Mayfield, Partech Ventures.
SeqOne Genomics is an AI-driven clinical‑genomics software company that converts next‑generation sequencing (NGS) data into actionable diagnostics for oncology, rare and inherited diseases, and multi‑omics applications, serving molecular labs and healthcare providers worldwide[3][5].
High-Level Overview
SeqOne’s mission is to scale genomic medicine by providing labs worldwide with AI‑powered bioinformatics that deliver faster, more precise, and clinically actionable genomic results[3]. Their platform is positioned as a clinical‑grade (CE‑IVD/IVDR) software solution for NGS interpretation, emphasizing speed, scalability, and data security for decentralized labs[3][7]. Key sectors include clinical oncology, rare disease diagnostics, liquid biopsy and somatic testing, and increasingly multi‑omics and pathogen detection after strategic acquisitions[5][7]. As a vendor to molecular laboratories and biopharma, SeqOne impacts the startup and clinical ecosystem by lowering the technical barrier for clinical NGS adoption, enabling smaller labs to offer precision diagnostics and accelerating commercialization paths for genomic diagnostics and biomarker programs[2][3][5].
Origin Story
SeqOne was founded in Montpellier, France, and incubated by SATT AxLR, launching its activities around 2017 with an emphasis on democratizing personalized medicine through software[3]. Founders and early team members combined genomics, bioinformatics and clinical diagnostics expertise to address the complexity and scale challenges of NGS interpretation; the company progressed from leading clinical NGS adoption in France to expanding globally with AI integration across germline, somatic and liquid biopsy workflows[3]. Key traction milestones include Series A / growth financings exceeding €30M before 2024, rapid customer growth (reported 3x growth to ~140 labs across 22 countries within a 12‑month span), and processing projections of over 110,000 patient analyses in 2025—signals of strong commercial momentum[3][5]. Recent strategic financing (€20M growth round) and acquisitions (e.g., Life & Soft, and acquisition of Congenica noted in company materials) further accelerated product breadth and international expansion, including U.S. market entry with a HIPAA‑compliant offering[5][7].
Core Differentiators
Role in the Broader Tech Landscape
SeqOne rides multiple converging trends: the clinicalization and decentralization of genomics, rising demand for scalable NGS interpretation as sequencing volumes grow, and the application of AI to reduce the manual bottleneck of variant curation[3][5]. Timing favors the company because regulatory clarity (IVDR/CE‑IVD), increasing reimbursement and adoption of precision oncology biomarkers, and the need for cloud/HIPAA‑compliant clinical software are all expanding market opportunity[3][5][7]. By enabling smaller and regional labs to deliver clinical‑grade genomic results, SeqOne influences the ecosystem by expanding access to personalized diagnostics, supporting pharma biomarker programs, and increasing competition among genomic software providers—potentially accelerating standardization of interpretation workflows and driving consolidation via partnerships and acquisitions[5][7].
Quick Take & Future Outlook
SeqOne’s near‑term trajectory appears focused on global expansion (notably the U.S.), deepening product capabilities across somatic/liquid biopsy and multi‑omics, and executing strategic acquisitions to broaden technical and geographic reach—backed by recent growth financing and reported customer expansion[5][7]. Key trends that will shape their journey include further integration of AI into regulatory‑grade diagnostics, payer and health‑system adoption of genomic testing, and competition from other bioinformatics platforms and integrated sequencing providers[3][5]. If SeqOne continues scaling validated clinical tests, maintaining regulatory/compliance posture, and executing M&A to fill capability gaps, it can strengthen its position as a leading pure‑software provider in clinical genomics and meaningfully expand access to precision medicine for decentralized labs worldwide[5][7].
Quick facts (selected)
If you’d like, I can:
SeqOne Genomics has raised $26.0M across 2 funding rounds. Most recently, it raised $23.0M Venture Round in May 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2025 | $23.0M Venture Round | Dispersion Capital, Elaia Partners, Khosla Ventures, Mayfield, Partech Ventures | |
| Mar 1, 2019 | $3.0M Seed | Dispersion Capital, Elaia Partners, Khosla Ventures, Mayfield, Partech Ventures |